A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results

BACKGROUND: Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm, phase II trial of regorafenib in advanced Ewing family sarcoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Attia, Steven, Bolejack, Vanessa, Ganjoo, Kristen N., George, Suzanne, Agulnik, Mark, Rushing, Daniel, Loggers, Elizabeth T., Livingston, Michael B., Wright, Jennifer, Chawla, Sant P., Okuno, Scott H., Reinke, Denise K., Riedel, Richard F., Davis, Lara E., Ryan, Christopher W., Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883574/
https://www.ncbi.nlm.nih.gov/pubmed/35950293
http://dx.doi.org/10.1002/cam4.5044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883574/
https://www.ncbi.nlm.nih.gov/pubmed/35950293
http://dx.doi.org/10.1002/cam4.5044

Ejemplares similares